诊断性非血管途径给予碘对比剂和钆对比剂后的超敏反应及药物过敏专科医师的作用
本文综述诊断性非血管途径给予碘对比剂和钆对比剂后超敏反应的风险与处理。非血管途径对比剂超敏反应风险很低,已发表个案多为离子型高渗对比剂所致速发型反应,钆对比剂未见报道。预防复发措施与血管内给药后类似,已弃用预用药,越来越提倡换用替代对比剂并参考过敏学分析结果。
要点
- 非血管途径对比剂超敏反应风险很低,可能与全身吸收极少有关。
- 已发表个案多为离子型高渗对比剂所致速发型反应,钆对比剂未见报道。
- 预防复发已弃用预用药,越来越提倡基于过敏学分析换用替代对比剂。
核心结论
- 非血管途径对比剂超敏反应风险很低,预防复发措施与血管内给药后类似,已弃用预用药,越来越提倡基于过敏学分析换用替代对比剂,特定情形下可减少预防措施。
研究设计与样本
- 综述,检索范围与纳入文献原文未报告。
临床应用与阅片要点
- 非血管途径使用对比剂前,应了解超敏反应风险很低,但仍有离子型高渗对比剂所致速发型反应的个案报道。
- 预防复发已弃用预用药,越来越提倡基于过敏学分析结果换用替代对比剂。
- 特定情形下可减少预防措施。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The risk of hypersensitivity reactions (HSR) following nonvascular administration of contrast media (CM) for diagnostic studies is very low, likely due to minimal absorption into the systemic circulation. Most published individual cases of HSR after nonvascular CM administration are immediate reactions caused by ionic high-osmolar CM, few by nonionic low-osmolar CM, and none by gadolinium-based contrast agents. Measures to prevent recurrent HSR following nonvascular administration are similar to those recommended to prevent HSR after intravascular CM administration. Premedication as preventive measure has been abandoned, while switching to an alternative CM, preferably based on the results of an allergological analysis, is increasingly advocated. In selected scenarios, preventive measures may be minimized.
引用
- van der Molen AJ, Vega F, A J M van de Ven A, et al. Hypersensitivity reactions after diagnostic nonvascular administration of iodine-based contrast media and gadolinium-based contrast agents and the role of the drug allergy specialist. Eur J Radiol. 2024. PMID: 39467397. doi:10.1016/j.ejrad.2024.111803
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。